|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
MaxCyte, Inc. Highlights High Titer Protein Production Using Biologically Relevant Cells in an Upcoming Educational Webinar Presentation
12/11/2012 11:05:05 AM
GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is hosting an educational webinar entitled Transient Transfection of Biologically Relevant Cells: CEVEC CAP-T™ Technology for High Yield Expression of Proteins in Human Derived Cells on Wednesday, December 12, 2012, from 11:00 AM – 12:00 PM EST. This scientific program will focus on the use of MaxCyte’s proprietary large scale transfection platform in combination with Cevec’s CAP-T technology for the production of proteins and antibodies with authentic human glycosylation and sialylation. Technical presentations will be given by Dr. James Brady, Director of Technical Applications at MaxCyte, and Dr. Hartmut Tintrup, VP Business Development & Licensing at Cevec Pharmaceuticals.
|
|
|
|
|
|
|
|
|
|
|